TY - JOUR
T1 - Threshold for the upper normal limit of indexed epicardial fat volume
T2 - Derivation in a healthy population and validation in an outcome-based study
AU - Shmilovich, Haim
AU - Dey, Damini
AU - Cheng, Victor Y.
AU - Rajani, Ronak
AU - Nakazato, Ryo
AU - Otaki, Yuka
AU - Nakanishi, Rine
AU - Slomka, Piotr J.
AU - Thomson, Louise E.J.
AU - Hayes, Sean W.
AU - Friedman, John D.
AU - Gransar, Heidi
AU - Wong, Nathan D.
AU - Shaw, Leslee J.
AU - Budoff, Matthew
AU - Rozanski, Alan
AU - Berman, Daniel S.
N1 - Funding Information:
This work was supported by Grant R21EB006829 from the National Institute of Biomedical Imaging and Bioengineering , Bethesda, Maryland (Dr. Dey) and the Eisner, Glazer, and Lincy Foundations , Beverly Hills, California (Dr. Berman). The EISNER1 cohort used was supported in part by Grant M01-RR00425 from the National Institutes of Health /National Center for Research Resources (NCRR)/General Clinical Research Centers (GCRC), Bethesda, Maryland. Dr. Shmilovich is a fellow of Save a Heart Foundation, Los Angeles, California, and receives a fellowship grant from the American Physician Fellowship for Medicine in Israel, Boston, Massacusetts.
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Epicardial fat volume (EFV) quantified on noncontrast cardiac computed tomography relates to cardiovascular prognosis. We sought to define the upper normal limit of body surface area (BSA)-indexed EFV (EFVi) in a healthy population and to validate it as a predictor of major adverse cardiovascular events (MACE). We analyzed noncontrast cardiac computed tomography scans of 226 healthy subjects with a low Framingham Risk Score (FRS; ≤6%) performed for coronary calcium scoring (CCS). EFV was quantified using validated software and indexed to BSA. We defined the 95th percentile as the upper normal limit. Subsequently, we reanalyzed a separate cohort of 232 participants from a previously published casecontrol study with 4-year follow-up and 58 cases of MACE to test the additive value of an abnormally high EFVi for predicting MACE. Of the 226 healthy participants 51% were men (mean age 52 ± 9 years). EFV correlated to BSA (r = 0.373, p <0.0001). Median, range, and 25th and 75th percentiles of the non-normally distributed EFVi were 33.3, 10.8 to 96.6, and 24.5 and 45.5 cm 3/m 2. The 95th percentile definition of the upper normal limit of EFVi was 68.1 cm 3/m 2. For prediction of MACE, EFVi values higher than the newly defined threshold emerged as a significant and independent predictor after controlling for confounders (odds ratio 2.8, 95% confidence interval 1.3 to 6.4, p = 0.012) and trended in its additive value to the combination of CCS <400 and FRS (area under the receiver operating characteristic curve 0.714 vs 0.675, p = 0.1277). In conclusion, in a healthy population we determined 68.1 cm 3/m 2 as the 95th percentile threshold for abnormally high EFVi. EFVi exceeding this value independently predicted MACE and trended to add to CCS and FRS in this prediction.
AB - Epicardial fat volume (EFV) quantified on noncontrast cardiac computed tomography relates to cardiovascular prognosis. We sought to define the upper normal limit of body surface area (BSA)-indexed EFV (EFVi) in a healthy population and to validate it as a predictor of major adverse cardiovascular events (MACE). We analyzed noncontrast cardiac computed tomography scans of 226 healthy subjects with a low Framingham Risk Score (FRS; ≤6%) performed for coronary calcium scoring (CCS). EFV was quantified using validated software and indexed to BSA. We defined the 95th percentile as the upper normal limit. Subsequently, we reanalyzed a separate cohort of 232 participants from a previously published casecontrol study with 4-year follow-up and 58 cases of MACE to test the additive value of an abnormally high EFVi for predicting MACE. Of the 226 healthy participants 51% were men (mean age 52 ± 9 years). EFV correlated to BSA (r = 0.373, p <0.0001). Median, range, and 25th and 75th percentiles of the non-normally distributed EFVi were 33.3, 10.8 to 96.6, and 24.5 and 45.5 cm 3/m 2. The 95th percentile definition of the upper normal limit of EFVi was 68.1 cm 3/m 2. For prediction of MACE, EFVi values higher than the newly defined threshold emerged as a significant and independent predictor after controlling for confounders (odds ratio 2.8, 95% confidence interval 1.3 to 6.4, p = 0.012) and trended in its additive value to the combination of CCS <400 and FRS (area under the receiver operating characteristic curve 0.714 vs 0.675, p = 0.1277). In conclusion, in a healthy population we determined 68.1 cm 3/m 2 as the 95th percentile threshold for abnormally high EFVi. EFVi exceeding this value independently predicted MACE and trended to add to CCS and FRS in this prediction.
UR - http://www.scopus.com/inward/record.url?scp=80955158515&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2011.07.031
DO - 10.1016/j.amjcard.2011.07.031
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 21880291
AN - SCOPUS:80955158515
SN - 0002-9149
VL - 108
SP - 1680
EP - 1685
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 11
ER -